Trousseau syndrome: management of refractory VTE

2.

Young

AM

,

Marshall

A

,

Thirlwall

J

, et al.

Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)

.

J Clin Oncol

.

2018

;

36

(

20

):

2017

-

2023

.

3.

Agnelli

G

,

Becattini

C

,

Meyer

G

, et al.;

Caravaggio Investigators

.

Apixaban for the treatment of venous thromboembolism associated with cancer

.

N Engl J Med

.

2020

;

382

(

17

):

1599

-

1607

.

4.

Lee

AY

,

Levine

MN

,

Baker

RI

, et al.;

Randomized Comparison of Low- Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators

.

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

.

N Engl J Med

.

2003

;

349

(

2

):

146

-

153

.

5.

Barca-Hernando

M

,

Ortega-Rivera

R

,

Lopez-Ruz

S

, et al.

Prognostic significance of incidental deep vein thrombosis in patients with cancer presenting with incidental pulmonary embolism

.

Cancers (Basel)

.

2020

;

12

(

8

):

2267

.

6.

Qdaisat

A

,

Wechsler

AH

,

Cruz Carreras

MT

, et al.

Concomitant deep vein thrombosis in cancer patients with unsuspected pulmonary embolism

.

Cancers (Basel)

.

2022

;

14

(

18

):

4510

.

7.

Karande

GY

,

Hedgire

SS

,

Sanchez

Y

, et al.

Advanced imaging in acute and chronic deep vein thrombosis

.

Cardiovasc Diagn Ther

.

2016

;

6

(

6

):

493

-

507

.

8.

Needleman

L

,

Cronan

JJ

,

Lilly

MP

, et al.

Ultrasound for lower extremity deep venous thrombosis: multidisciplinary recommendations from the Society of Radiologists in Ultrasound consensus conference

.

Circulation

.

2018

;

137

(

14

):

1505

-

1515

.

9.

Prandoni

P

,

Lensing

AW

,

Prins

MH

, et al.

Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism

.

Ann Intern Med

.

2002

;

137

(

12

):

955

-

960

.

10.

Tan

M

,

Mol

GC

,

van Rooden

CJ

, et al.

Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis

.

Blood

.

2014

;

124

(

4

):

623

-

627

.

11.

van Dam

LF

,

Dronkers

CEA

,

Gautam

G

, et al.;

Theia Study Group

.

Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis

.

Blood

.

2020

;

135

(

16

):

1377

-

1385

.

12.

de Jong

CMM

,

Kroft

LJM

,

van Mens

TE

,

Huisman

MV

,

Stöger

JL

,

Klok

FA

.

Modern imaging of acute pulmonary embolism

.

Thromb Res

.

2024

;

238

:

105

-

116

.

13.

van Dam

LF

,

Dronkers

CEA

,

Gautam

G

, et al.;

Theia Study Group

.

Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis

.

Blood

.

2020

;

135

(

16

):

1377

-

1385

.

14.

Kaptein

FHJ

,

van der Hulle

T

,

Braken

SJE

, et al.

Prevalence, treatment, and prognosis of tumor thrombi in renal cell carcinoma

.

JACC CardioOncol

.

2022

;

4

(

4

):

522

-

531

.

15.

Kaufman

LB

,

Yeh

BM

,

Breiman

RS

,

Joe

BN

,

Qayyum

A

,

Coakley

FV

.

Inferior vena cava filling defects on CT and MRI

.

AJR Am J Roentgenol

.

2005

;

185

(

3

):

717

-

726

.

16.

He

X

,

Anthony

DC

,

Catoni

Z

,

Cao

W.

Pulmonary tumor embolism: a retrospective study over a 30-year period

.

PLoS One

.

2021

;

16

(

8

):

e0255917

.

17.

Rana

MK

,

Rahman

O

,

O'Brien

A.

Primary pulmonary angiosarcoma

.

BMJ Case Rep

.

2021

;

14

(

11

).

18.

Sarswat

S

,

Khan

D

,

Sagar

S

,

Kumar

R.

Role of 18 F-FDG PET/CT in the diagnosis of benign vs. malignant tumor thrombus

.

Nucl Med Commun

.

2023

;

44

(

8

):

726

-

731

.

19.

Pei

X

,

Lu

M

,

Liu

Z

, et al.

The value of enhanced multiparameteric MRI diagnostic model for preoperatively predicting surgical methods of inferior vena cava in patients with renal tumors and inferior vena cava tumor thrombus

.

BMC Med Imaging

.

2023

;

23

(

1

):

86

.

20.

Hutchinson

R

,

Rew

C

,

Chen

G

, et al.

The adverse survival implications of bland thrombus in renal cell carcinoma with venous tumor thrombus

.

Urology

.

2018

;

115

:

119

-

124

.

21.

Aly

AK

,

Moussa

AM

,

Chevallier

O

, et al.

Iliocaval and iliofemoral venous stenting for obstruction secondary to tumor compression

.

CVIR Endovasc

.

2024

;

7

(

1

):

33

.

22.

Pouncey

AL

,

Kahn

T

,

Morris

RI

,

Saha

P

,

Thulasidasan

N

,

Black

SA

.

Risk factors and classification of reintervention following deep venous stenting for acute iliofemoral deep vein thrombosis

.

J Vasc Surg Venous Lymphat Disord

.

2022

;

10

(

5

):

1051

-

1058.e31058e3

.

23.

van der Wall

SJ

,

Klok

FA

,

den Exter

PL

, et al.

Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice

.

J Thromb Haemost

.

2017

;

15

(

1

):

74

-

79

.

24.

Schaefer

JK

,

Li

M

,

Wu

Z

, et al.

Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs

.

J Thromb Haemost

.

2021

;

19

(

1

):

212

-

220

.

25.

Owusu

T

,

Derkach

A

,

Burge

M

,

Nemirovsky

D

,

Zwicker

JI

.

Bleeding and thrombosis in patients with cancer and acute venous thromboembolism requiring urgent procedures

.

Blood

.

2023

;

142

(

suppl 1

):

2656

.

26.

Bertoletti

L

,

Ollier

E

,

Duvillard

C

, et al.

Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism

.

Pharmacol Res

.

2017

;

118

:

33

-

42

.

27.

Ip

BY

,

Ko

H

,

Wong

GL

, et al.

Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis

.

CNS Drugs

.

2022

;

36

(

12

):

1313

-

1324

.

28.

Perlman

A

,

Wanounou

M

,

Goldstein

R

,

Choshen Cohen

L

,

Singer

DE

,

Muszkat

M.

Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA Adverse Event Reporting System (FAERS)

.

CNS Drugs

.

2019

;

33

(

12

):

1223

-

1228

.

29.

Acton

EK

,

Hennessy

S

,

Gelfand

MA

, et al.

Direct-acting oral anticoagulants and antiseizure medications for atrial fibrillation and epilepsy: risk of thromboembolic and major bleeding events

.

JAMA Neurol

.

2024

.

30.

Kumar

R

,

Bhandari

S

,

Singh

SRK

,

Malapati

S

,

Cisak

KI

.

Incidence and outcomes of heparin-induced thrombocytopenia in solid malignancy: an analysis of the national inpatient sample database

.

Br J Haematol

.

2020

;

189

(

3

):

543

-

550

.

31.

Croles

FN

,

Lukens

MV

,

Mulder

R

,

de Maat

MPM

,

Mulder

AB

,

Meijer

K.

Monitoring of heparins in antithrombin-deficient patients

.

Thromb Res

.

2019

;

175

:

8

-

12

.

32.

Zwicker

JI

,

Wang

T-F

,

DeAngelo

D-J

, et al.

The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH

.

J Thromb Haemost

.

2020

;

18

(

2

):

278

-

284

.

33.

Dufrost

V

,

Risse

J

,

Zuily

S

,

Wahl

D.

Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature

.

Curr Rheumatol Rep

.

2016

;

18

(

12

):

74

.

34.

Tota

V

,

Dagonnier

M

,

Wery

D

, et al.

Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: case report and systematic review

.

Lung Cancer

.

2021

;

160

:

59

-

65

.

35.

Gupta

A

,

Shah

U

,

Khine

H

,

Vandergriff

T

,

Froehlich

T.

Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy

.

Melanoma Res

.

2017

;

27

(

2

):

171

-

173

.

36.

Capecchi

M

,

Abbattista

M

,

Ciavarella

A

,

Uhr

M

,

Novembrino

C

,

Martinelli

I.

Anticoagulant therapy in patients with antiphospholipid syndrome

.

J Clin Med

.

2022

;

11

(

23

):

6984

.

37.

Baumann Kreuziger

L

,

Onwuemene

O

,

Kolesar

E

,

Crowther

M

,

Lim

W.

Systematic review of anticoagulant treatment of catheter-related thrombosis

.

Thromb Res

.

2015

;

136

(

6

):

1103

-

1109

.

38.

Byon

W

,

Nepal

S

,

Schuster

AE

,

Shenker

A

,

Frost

CE

.

Regional gastrointestinal absorption of apixaban in healthy subjects

.

J Clin Pharmacol

.

2018

;

58

(

7

):

965

-

971

.

39.

Cada

DJ

,

Levien

TL

,

Baker

DE

.

Apixaban

.

Hosp Pharm

.

2013

;

48

(

6

):

494

-

509

.

40.

Hakeam

HA

,

Al-Sanea

N.

Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)

.

J Thromb Thrombolysis

.

2017

;

43

(

3

):

343

-

351

.

41.

Martin

KA

,

Beyer-Westendorf

J

,

Davidson

BL

,

Huisman

MV

,

Sandset

PM

,

Moll

S.

Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation

.

J Thromb Haemost

.

2021

;

19

(

8

):

1874

-

1882

.

42.

Kubitza

D

,

Becka

M

,

Zuehlsdorf

M

,

Mueck

W.

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects

.

J Clin Pharmacol

.

2006

;

46

(

5

):

549

-

558

.

43.

Zhang

L

,

Peters

G

,

Haskell

L

,

Patel

P

,

Nandy

P

,

Moore

KT

.

A cross-study analysis evaluating the effects of food on the pharmacokinetics of rivaroxaban in clinical studies

.

J Clin Pharmacol

.

2017

;

57

(

12

):

1607

-

1615

.

44.

Hamulyák

EN

,

Daams

JG

,

Leebeek

FWG

, et al.

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

.

Blood Adv

.

2021

;

5

(

1

):

113

-

121

.

45.

Zwicker

JI

,

Paranagama

D

,

Lessen

DS

,

Colucci

PM

,

Grunwald

MR

.

Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study

.

Haematologica

.

2022

;

107

(

5

):

1106

-

1110

.

46.

Ortel

TL

,

Neumann

I

,

Ageno

W

, et al.

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

.

Blood Adv

.

2020

;

4

(

19

):

4693

-

4738

.

47.

Carrier

M

,

Le Gal

G

,

Cho

R

,

Tierney

S

,

Rodger

M

,

Lee

AY

.

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients

.

J Thromb Haemost

.

2009

;

7

(

5

):

760

-

765

.

48.

Ihaddadene

R

,

Le Gal

G

,

Delluc

A

,

Carrier

M.

Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis

.

Thromb Res

.

2014

;

134

(

1

):

93

-

95

.

49.

Schulman

S

,

Zondag

M

,

Linkins

L

, et al.

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis

.

J Thromb Haemost

.

2015

;

13

(

6

):

1010

-

1018

.

50.

Guan

Z

,

Wang

R

,

Hussain

RH

,

Fredenburgh

JC

,

Jaffer

IH

,

Weitz

JI

.

Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro

.

J Thromb Haemost

.

2023

;

21

(

1

):

76

-

82

.